Pages that link to "Q86003442"

The following pages link to Differential expression of natural killer cell activating receptors in blood versus bone marrow in patients with monoclonal gammopathy (Q86003442):

Displaying 20 items.

• The cellular immune system in myelomagenesis: NK cells and T cells in the development of myeloma [corrected] and their uses in immunotherapies (Q35669068) (← links)
• T cells in multiple myeloma display features of exhaustion and senescence at the tumor site. (Q37390723) (← links)
• Multiple solitary plasmacytoma with multifocal bone involvement. First clinical case report in a uraemic patient (Q38109553) (← links)
• Immune defects in the risk of infection and response to vaccination in monoclonal gammopathy of undetermined significance and multiple myeloma (Q38219408) (← links)
• Optimal selection of natural killer cells to kill myeloma: the role of HLA-E and NKG2A (Q38881386) (← links)
• Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma (Q38907104) (← links)
• Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells (Q39037600) (← links)
• Activation of NK cells and disruption of PD-L1/PD-1 axis: two different ways for lenalidomide to block myeloma progression (Q39136762) (← links)
• Role of Distinct Natural Killer Cell Subsets in Anticancer Response (Q39210022) (← links)
• Novel anti-myeloma immunotherapies targeting the SLAM family of receptors (Q39389614) (← links)
• Natural killer cells modulation in hematological malignancies (Q41982546) (← links)
• Effects of 5-azacytidine on natural killer cell activating receptor expression in patients with refractory anemia with excess of blasts (Q41994454) (← links)
• Restoring Natural Killer Cell Immunity against Multiple Myeloma in the Era of New Drugs. (Q49830211) (← links)
• Natural killer cells in acute myeloid leukemia patients: from phenotype to transcriptomic analysis (Q51600879) (← links)
• Elotuzumab for the Treatment of Relapsed or Refractory Multiple Myeloma, with Special Reference to its Modes of Action and SLAMF7 Signaling. (Q55310350) (← links)
• The anti-SLAMF7 antibody elotuzumab mediates NK cell activation through both CD16-dependent and -independent mechanisms. (Q55409204) (← links)
• Natural killer cells and other innate lymphoid cells in cancer (Q57395724) (← links)
• Myeloma Bone Disease: Update on Pathogenesis and Novel Treatment Strategies (Q57794000) (← links)
• Key Role of the CD56CD16 Natural Killer Cell Subset in the Recognition and Killing of Multiple Myeloma Cells (Q60926720) (← links)
• CAR-Expressing Natural Killer Cells for Cancer Retargeting. (Q64970629) (← links)